3,560 material Form 8-K filings that 2,489 companies we cover made with the SEC in October 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 2,508 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
A Delaware Court of Chancery granted FBB Holdings I's motions and enjoined Destination XL from terminating its merger agreement with FBB while the court makes further expedited determinations. The order is temporary and not a ruling on the merits, and DXL says it believes FBB's claims are without merit and will defend against them.
The Court of Chancery held a hearing on October 29, 2026 and granted both motions after it.
The merger agreement, dated December 11, 2025, allows either party to terminate if the merger is not completed by October 30, 2026.
FBB filed its complaint on October 26, 2026; DXL filed an answer and counterclaims on October 28, 2026.
DXL's preliminary proxy statement was filed July 17, 2026 and amended most recently on October 19, 2026.
Annovis Bio received a New York Stock Exchange notice on October 29, 2026, that it no longer meets continued listing standards because its 30-day average market capitalization and stockholders' equity were both below $50 million. The company has 9 months to regain compliance, and its common stock will keep trading under the symbol ANVS with a ".BC" designation while it works on a plan.
NYSE notice received October 29, 2026, under Section 802.01B of its Listed Company Manual
30-day average market capitalization was approximately $48.4 million as of October 28, 2026
Stockholders' deficit was approximately $(4.3) million as of June 30, 2026
Company must submit a compliance plan within 45 days of the notice; cure period is 9 months
Alset Inc. received a Nasdaq notice on October 28, 2026, because its closing bid price was below $1.00 for 30 consecutive trading days. The company has until April 26, 2027 to regain compliance, and the notice has no immediate effect on its listing, but failure to comply could lead to delisting proceedings.
Nasdaq notice dated October 28, 2026 cites a closing bid price below $1.00 for 30 consecutive trading days
Compliance deadline is April 26, 2027; regaining it requires a closing bid of at least $1.00 for 10 consecutive business days
The company previously announced a planned 1-for-5 reverse stock split and expects to announce its timing soon
Bridger Aerospace received a Nasdaq deficiency letter on October 28, 2026, because its common stock closed below $1.00 per share for 30 consecutive business days ended October 27, 2026. The letter has no immediate effect, and the stock continues to trade on The Nasdaq Global Market as BAER, but the company must regain compliance or face possible delisting.
Nasdaq letter dated October 28, 2026 cites a minimum bid price of $1.00 per share under Listing Rule 5450(a)(1)
Compliance period runs until April 26, 2027
Regaining compliance requires a closing bid of at least $1.00 for ten consecutive business days, unless Nasdaq extends that period
The company may consider a reverse stock split if necessary; it cannot assure it will regain compliance
Nasdaq's Listing Qualifications Department issued a Staff Delisting Determination because the company's bid price stayed below $1.00 for 30 consecutive business days, and it is not eligible for a compliance period after its cumulative reverse stock splits totaled 1-for-2,000. The company intends to request a hearing before a Nasdaq Panel, which would stay the suspension; otherwise trading is scheduled to be suspended on November 5, 2026. Shareholders also approved raising authorized shares to 850,000,000, with the amendment effective October 30, 2026.
Nasdaq letter dated October 27, 2026 cites a closing bid price below $1.00 from September 15 through October 26, 2026.
Company is not eligible for a 180-day compliance period after 1-for-10 (July 8, 2025), 1-for-20 (May 8, 2026) and 1-for-10 (October 27, 2026) reverse splits.
Hearing request and $20,000 fee must reach Nasdaq by 4:00 p.m. Eastern Time on November 3, 2026, or trading is suspended at the opening on November 5, 2026.
Shareholders approved increasing authorized shares from 350,000,000 to 850,000,000; the proposal received 2,221,561 votes for and 53,946 against.
Actuate Therapeutics received a Nasdaq notice on October 28, 2026, stating its stock closed below the $1.00 minimum bid price for 30 consecutive business days. The company has until April 26, 2027 to regain compliance, and the stock continues to trade on The Nasdaq Global Market as ACTU for now. If it does not regain compliance, the stock could become subject to delisting, which matters to shareholders.
Nasdaq notice received October 28, 2026 under Listing Rule 5450(a)(1)
Compliance deadline is April 26, 2027; stock must close at or above $1.00 for at least 10 consecutive business days
Separate July 15, 2026 notice on minimum market value of listed securities; regain compliance by January 11, 2027
A second 180-day period may be available if the company moves its listing to the Nasdaq Capital Market
Neumora Therapeutics received a Nasdaq notice on October 26, 2026 that its common stock is below the $1.00 minimum bid price required for continued listing on the Nasdaq Global Select Market. The company has 180 calendar days, until April 26, 2027, to regain compliance, and the filing states there can be no assurance it will do so, which raises the risk of future delisting for shareholders.
Nasdaq notice received October 26, 2026 under Listing Rule 5450(a)(1) for the $1.00 minimum bid price
Compliance period runs 180 calendar days, until April 26, 2027
Regaining compliance requires a closing bid of at least $1.00 per share for ten consecutive business days
If not compliant, the company may need to apply to transfer to The Nasdaq Capital Market and may consider a reverse stock split
Game Your Game Inc. (GYGY) received a Nasdaq notice that its stock has traded below the $1.00 minimum bid price for 30 consecutive business days, and it has until April 26, 2027 to regain compliance. The company's shares remain listed on the Nasdaq Capital Market for now, but failure to cure could lead to delisting proceedings.
Nasdaq letter dated October 27, 2026 cites closing bid below $1.00 over 30 business days ending October 26, 2026
Compliance period runs 180 calendar days to April 26, 2027; shares must close at or above $1.00 for 10 consecutive business days
Veronica V. Montenegro appointed to the board effective October 28, 2026, as governance committee chair and audit and compensation committee member
Director pay: $50,000 annual cash retainer, $27,500 additional cash for committee roles, and $77,500 in annual stock option grants
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.